Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune, Inflammatory, and Oncology Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PS beta-8 (PSMB8) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PS beta-8 (PSMB8) Recombinant Protein High purity (>95%), Endotoxin Controlled (<1EU/ug), Sequence Verified. Theoretical MW confirmed. |
View PSMB8 Products |
| Gene Delivery | PS beta-8 (PSMB8) Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and expression validation. |
View PSMB8 Products |
| Benchmark Ab | Anti-PS beta-8 (PSMB8) Recombinant Antibody Sequence-derived positive control for assay development and validation. |
View PSMB8 Products |
| Validator | PS beta-8 (PSMB8) siRNA Set Target-specific knockdown verification in cellular assays. |
View PSMB8 Products |
| Related Target A | PSMB5 (Proteasome subunit beta type-5) Constitutive proteasome counterpart; essential for off-target selectivity screening. |
View PSMB5 Products |
| Related Target B | PSMB9 (LMP2) Co-functional immunoproteasome subunit; key target for dual-selective inhibitor profiles. |
View PSMB9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against constitutive proteasomes | Matched pair of high-purity PSMB8 and PSMB5 recombinant proteins for parallel IC50 screening. |
| Assay reproducibility and enzyme stability | Sequence-verified, endotoxin-controlled recombinant proteins with strict batch-to-batch consistency. |
| Enzymatic activity preservation | Native-like folding and strict purification protocols to ensure functional integrity. |
| Lack of established reference controls | Recombinant benchmark antibodies matching clinical-stage reference sequences; validated control antibodies and siRNA included. |
| Target validation and off-target confirmation | Validated siRNA sets for sequence-specific gene silencing in cellular functional assays. |
Live PS beta-8 (PSMB8) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the immunoproteasome subunit PS beta-8 (also known as PSMB8 or LMP7) represents a major shift in treating autoimmune disorders and hematological malignancies. Unlike broad-spectrum proteasome inhibitors (e.g., bortezomib) which target both constitutive and immunoproteasomes, selective PS beta-8 inhibition spares the constitutive proteasome (PSMB5), significantly reducing systemic toxicities such as peripheral neuropathy and thrombocytopenia. As first-generation therapies (e.g., zetomipzomib) reach the clinic, the next wave of R&D is targeting highly selective non-covalent inhibitors and PROTAC degraders to further minimize off-target toxicity. The primary therapeutic focus has shifted from oncology toward chronic inflammatory and autoimmune indications, including Lupus Nephritis, Rheumatoid Arthritis, and Dermatomyositis, where immunoproteasome activity is highly upregulated in immune cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Selective Inhibitors) | Kezar Life Sciences, Merck KGaA, Academic/Pharma | Lupus Nephritis, Rheumatoid Arthritis, Inflammatory Bowel Disease | Enzymatic Selectivity Assay (Requires highly pure PSMB8 vs PSMB5 proteins) |
| PROTACs / Degraders | Academic & Biotech Consortia, Emerging Biotech | Multiple Myeloma, Solid Tumors | Degradation Kinetics (Requires Lentiviral-driven stable expression lines; specific antibodies & cell lines) |
| Monoclonal Antibodies / Research Tools | Diagnostic & Discovery Players | Biomarker Detection, Immunohistochemistry | Epitope Specificity (Requires sequence-verified antigen standards) |
Molecular Differentiation & Assay Strategy
To develop a best-in-class PS beta-8 drug, key differentiation metrics must be addressed:
- Selectivity vs PSMB5: >100-fold selectivity to avoid constitutive proteasome toxicity.
- Binding Kinetics: Covalent reversible binding preferred for reduced off-target risk; assess via SPR or washout assays.
- Intracellular Target Engagement: Use activity-based probes or CETSA for cellular quantification.
TarMart provides high-purity recombinant PSMB8 and PSMB5 proteins (endotoxin-controlled, sequence-verified) for enzymatic counter-screening, lentiviral overexpression systems for degradation studies, and validated siRNA for target knockdown verification.